Close

Alexion Pharmaceuticals (AXLN) Announces Interim Results from Phase I/II Trial of Samalizumab

December 6, 2010 8:20 AM EST Send to a Friend
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced Monday the the interim results of its first Phase I/II trial of samalizumab, which ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login